China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its first commercial surgery using the Iberis multi-electrode renal radiofrequency denervation (RDN) system in Germany. The procedure was performed by Dr. Saarraaken Kulenthiran at the University Hospital of Saarland, with no complications or adverse events reported.
Product Highlights
The Iberis RDN system, which received approval in China last week as an adjuvant therapy for refractory hypertension and hypertension patients with drug intolerance, is the only approved RDN product worldwide featuring both transradial approach (TRA) and transfemoral approach (TFA). This dual-approach capability offers greater flexibility and options for physicians in treating patients with hypertension.-Fineline Info & Tech
Leave a Reply